Blum Robert I sold $491K of CYTK

HC Wainwright & Co. maintained a Buy rating on Cytokinetics (CYTK) with a $140 price target, suggesting a 126% upside from the Oct 16 close. The firm cited strong clinical data from the Phase 3 ACACIA-HCM trial and promising market potential for aficamten, highlighting its benefits for hypertrophic cardiomyopathy patients.

Cytokinetics (CYTK) received Health Canada approval for MYQORZO (aficamten) to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on Phase 3 SEQUOIA-HCM trial results showing improved exercise capacity. MYQORZO is a once-daily oral cardiac myosin inhibitor. The stock is up 0.64% at $62.35.

Cytokinetics (CYTK) received Health Canada approval for MYQORZO (aficamten) to treat adult NYHA class II-III obstructive HCM, marking its fifth approval after the U.S., China, EU, and U.K. The company anticipates Canadian pricing, reimbursement, and launch timing as next catalysts, along with an sNDA for nHCM in Q4 2026.

Cytokinetics (CYTK) announced Health Canada approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. This is the fifth approval for MYQORZO in less than a year, following U.S., China, EU, and UK approvals. The approval is based on positive Phase 3 trial results showing improved exercise capacity and symptoms. MYQORZO is a once-daily oral cardiac myosin inhibitor.

William Blair initiated coverage on Cytokinetics (NASDAQ:CYTK) with an Outperform rating and $101 price target, citing 58% upside potential. The firm expects commercial launch of MYQORZO by 2027 and $3.74B sales by 2032. Other analysts maintain bullish views, while the company faces legal action against Bristol-Myers Squibb and MyoKardia.

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.